Despite the increasing knowledge of the genomic landscape of acute myeloid leukemia (AML), prediction merely based on genetics fails to anticipate outcome, presumably due to the heterogeneous composition of the leukemic clone determining complex interactions between different genetic abnormalities. Therefore, the introduction of a post-treatment biomarker exploring the quality of response to therapy such as assessment of measurable (previously minimal) residual disease (MRD) may lead to refinements of the prognostic assessment in AML. In this view, the European LeukemiaNet has recently endorsed the achievement of a MRD negative morphologic complete remission as a purpose the treatment. Techniques like multiparametric flow cytometry and reverse transcriptase-quantitative polymerase chain reaction have reached a level of sensitivity and specificity that make them ready for introduction in clinical practice. In the present review, we will give an update on the efforts in harmonization and/or standardization of MRD assessment in AML, focusing on the newest acquisitions in the clinical applications of MRD, and considering issues like relationship of MRD with leukemic stem cells or MRD assessment in peripheral blood. (C) 2018 Elsevier Inc. All rights reserved.

Buccisano, F., Maurillo, L., Schuurhuis, G.j., Del Principe, M.i., Di Veroli, A., Gurnari, C., et al. (2019). The emerging role of measurable residual disease detection in AML in morphologic remission. SEMINARS IN HEMATOLOGY, 56(2), 125-130 [10.1053/j.seminhematol.2018.09.001].

The emerging role of measurable residual disease detection in AML in morphologic remission

Buccisano, F;Del Principe, M I;Di Veroli, A;Venditti, A
2019-04-01

Abstract

Despite the increasing knowledge of the genomic landscape of acute myeloid leukemia (AML), prediction merely based on genetics fails to anticipate outcome, presumably due to the heterogeneous composition of the leukemic clone determining complex interactions between different genetic abnormalities. Therefore, the introduction of a post-treatment biomarker exploring the quality of response to therapy such as assessment of measurable (previously minimal) residual disease (MRD) may lead to refinements of the prognostic assessment in AML. In this view, the European LeukemiaNet has recently endorsed the achievement of a MRD negative morphologic complete remission as a purpose the treatment. Techniques like multiparametric flow cytometry and reverse transcriptase-quantitative polymerase chain reaction have reached a level of sensitivity and specificity that make them ready for introduction in clinical practice. In the present review, we will give an update on the efforts in harmonization and/or standardization of MRD assessment in AML, focusing on the newest acquisitions in the clinical applications of MRD, and considering issues like relationship of MRD with leukemic stem cells or MRD assessment in peripheral blood. (C) 2018 Elsevier Inc. All rights reserved.
apr-2019
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Acute Myeloyd Leukemia; Biomarkers; Minimal Measurable Disease; Multiparametric Flow Cytometri; RT-qPCR; Risk-adapted therapy
Buccisano, F., Maurillo, L., Schuurhuis, G.j., Del Principe, M.i., Di Veroli, A., Gurnari, C., et al. (2019). The emerging role of measurable residual disease detection in AML in morphologic remission. SEMINARS IN HEMATOLOGY, 56(2), 125-130 [10.1053/j.seminhematol.2018.09.001].
Buccisano, F; Maurillo, L; Schuurhuis, Gj; Del Principe, Mi; Di Veroli, A; Gurnari, C; Venditti, A
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
BUCCISANO.pdf

solo utenti autorizzati

Licenza: Copyright dell'editore
Dimensione 3.73 MB
Formato Adobe PDF
3.73 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/311902
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 27
  • ???jsp.display-item.citation.isi??? 26
social impact